NextTrip (NTRP) 10-K 24 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 20, 2020	Jun. 30, 2019
Document And Entity Information
Entity Registrant Name	SIGMA LABS, INC.
Entity Central Index Key	0000788611
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 14,706,518
Entity Common Stock, Shares Outstanding		1,627,182
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 86,919	$ 1,279,782
Accounts Receivable, net	55,540	38,800
Note Receivable, net		121,913
Inventory	598,718	240,086
Prepaid Assets	199,727	67,255
Total Current Assets	940,904	1,747,836
Other Assets:
Property and Equipment, net	128,723	277,944
Intangible Assets, net	569,341	404,978
Investment in Joint Venture	500	500
Long-Term Prepaid Asset	52,000
Total Other Assets	750,564	683,422
TOTAL ASSETS	1,691,468	2,431,258
Current Liabilities:
Accounts Payable	727,114	217,488
Note Payable	50,000	50,000
Deferred Revenue	139,447	51,498
Accrued Expenses	122,658	376,833
Total Current Liabilities	1,039,219	695,819
Long-Term Liabilities
TOTAL LIABILITIES	1,039,219	695,819
Commitments & Contingencies
Stockholders' Equity
Preferred Stock, $0.001 par; 10,000,000 shares authorized; none issued and outstanding
Common Stock, $0.001 par; 2,250,000 shares authorized; 1,403,759 and 877,663 issued and outstanding, respectively	1,404	878
Additional Paid-In Capital	26,746,439	21,509,306
Accumulated Deficit	(26,095,594)	(19,774,745)
Total Stockholders' Equity	652,249	1,735,439
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 1,691,468	$ 2,431,258

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,250,000	2,250,000
Common stock, shares issued	1,403,759	877,663
Common stock, shares outstanding	1,403,759	877,663

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
REVENUES	$ 402,446	$ 388,574
COST OF REVENUE	574,301	270,107
GROSSPROFIT (LOSS)	(171,855)	118,467
EXPENSES:
Salaries & Benefits	2,354,329	2,056,584
Stock-Based Compensation	797,240	1,145,530
Operating R&D Costs	647,994	493,410
Investor & Public Relations	703,710	633,035
Legal & Professional Service Fees	664,403	564,854
Office Expenses	692,881	466,657
Depreciation & Amortization	192,569	192,374
Other Operating Expenses	158,706	134,827
Total Operating Expenses	6,211,830	5,687,271
LOSS FROM OPERATIONS	(6,383,685)	(5,568,804)
OTHER INCOME (EXPENSE)
Interest Income	18,760	35,178
State Incentives	51,877
Bad Debt Expense	(2,500)
Exchange Rate Gain (Loss)	(4,879)	162
Other Income	8,263
Interest Expense	(8,685)	(3,966)
Loss on Disposal of Assets		(36,733)
Total Other Income (Expense)	62,836	(5,359)
LOSS BEFORE PROVISION FOR INCOME TAXES	(6,320,849)	(5,574,163)
Provision for Income Taxes
Net Loss	(6,320,849)	(5,574,163)
Preferred Dividends		(15,125)
Net Loss applicable to Common Stockholders	$ (6,320,849)	$ (5,589,288)
Net Loss per Common Share - Basic and Diluted	$ (5.37)	$ (8.10)
Weighted Average Number of Shares Outstanding - Basic and Diluted	1,176,278	689,805

Statement of Stockholders' Equi

Statement of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 498	$ 17,196,875	$ (14,185,457)	$ 3,011,916
Balance, shares at Dec. 31, 2017	497,893
Shares Issued for Services - net of forfeitures	$ 20	256,244		256,264
Shares Issued for Services - net of forfeitures, shares	20,000
Shares and warrants sold in public offering, net of offering costs	$ 204	1,722,196		1,722,400
Shares and warrants sold in public offering, net of offering costs, shares	204,000
Convertible preferred shares sold		1,224,000		1,224,000
Shares issued for conversion of preferred	$ 135	(135)
Shares issued for conversion of preferred, shares	135,000
Shares issued from Exercise of Warrants	$ 18	192,114		192,132
Shares issued from Exercise of Warrants, shares	17,790
Shares issued for note & accrued interest conversion	$ 32	49,998		50,000
Shares issued for note & accrued interest conversion, shares	2,500
Shares Issued for Cashless Exchange of Warrants	$ 1	(1)
Shares Issued for Cashless Exchange of Warrants, shares	480
Preferred dividends paid upon conversion			(15,125)	(15,125)
Preferred dividends paid upon conversion, shares
Stock based compensation		868,015		868,015
Net loss			(5,574,163)	(5,574,163)
Balance at Dec. 31, 2018	$ 878	21,509,306	(19,774,745)	1,735,439
Balance, shares at Dec. 31, 2018	877,663
Shares Issued for Services - net of forfeitures	$ 23	320,087		320,110
Shares Issued for Services - net of forfeitures, shares	22,650
Shares and warrants sold in public offering, net of offering costs	$ 447	3,816,345		3,816,792
Shares and warrants sold in public offering, net of offering costs, shares	447,580
Shares issued from Exercise of Warrants	$ 7	75,841		75,848
Shares issued from Exercise of Warrants, shares	7,023
Stock based compensation		494,240		494,240
Warrants issued for services		15,569		15,569
Shares sold in PIPE, net of offering costs	$ 40	514,960		515,000
Shares sold in PIPE, net of offering costs, shares	40,000
UPO proceeds in Public Offering		100		100
Shares issued for cashless exchange of unit purchase options	$ 9	(9)
Shares issued for cashless exchange of unit purchase options, shares	8,843
Net loss			(6,320,849)	(6,320,849)
Balance at Dec. 31, 2019	$ 1,404	$ 26,746,439	$ (26,095,594)	$ 652,249
Balance, shares at Dec. 31, 2019	1,403,759

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
OPERATING ACTIVITIES
Net Loss	$ (6,320,849)	$ (5,574,163)
Noncash Expenses:
Depreciation and Amortization	192,569	192,374
Stock Based Compensation	797,240	1,145,530
Stock Issued for Third Party Services	17,110
Warrants Issued for Third Party Services	15,569
Loss on Write-off of Asset		36,733
Change in assets and liabilities:
Accounts Receivable	(16,740)	65,738
Interest Receivable		34,390
Inventory	(358,632)	(24,844)
Prepaid Assets	(184,472)	(1,652)
Accounts Payable	509,626	116,604
Deferred Revenue	87,949	15,818
Accrued Expenses	(254,175)	230,501
NET CASH USED IN OPERATING ACTIVITIES	(5,514,805)	(3,762,971)
INVESTING ACTIVITIES
Purchase of Property and Equipment	(33,487)	(79,116)
Purchase of Intangible Assets	(174,224)	(149,409)
Payment Received from Notes Receivable	121,913	632,197
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(85,798)	403,672
FINANCING ACTIVITIES
Gross Proceeds from issuance of Convertible Preferred and Warrants		1,350,000
Gross Proceeds from issuance of Common Stock and Warrants	4,981,221	2,040,100
Less Offering Costs	(649,329)	(433,700)
Proceeds from exercise of Warrants	75,848	192,132
Dividends on Preferred		(15,125)
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,407,740	3,123,407
NET CHANGE IN CASH FOR PERIOD	(1,192,863)	(235,892)
CASH AT BEGINNING OF PERIOD	1,279,782	1,515,674
CASH AT END OF PERIOD	86,919	1,279,782	$ 1,515,674
Noncash investing and financing activities disclosure:
Conversion of Convertible Debt for Stock		(50,000)
Common Stock Issued for Conversion of Series B&C Preferred		1,350
Common Stock Issued for Cashless Exchange of Warrants		5
Common Stock Issued for Cashless Exchange of Unit Purchase Options	88
Issuance of Common Stock and Warrants for services	335,679	256,264
Interest	5,069	12,205
Income Taxes

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 1 – Summary of Significant Accounting Policies Nature of Business Reverse Stock Split Basis of Presentation Continuing Operations In 2019, the Company relied on both public and private offerings to finance the commencement of commercialization by entering test and evaluation programs with large potential customers, both end-users and OEMs. On March 15, 2019, the Company closed a public offering of equity securities resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by the Company. In May 2019, the Company closed a private placement of equity securities resulting in net proceeds of approximately $515,000, after deducting placement agent commissions and other offering expenses payable by the Company. In August 2019, the Company closed a public offering of equity securities resulting in net proceeds of approximately $1,971,000, after deducting placement agent commissions and other offering expenses payable by the Company. In September 2019, Aegis Capital Corp. partially exercised its over-allotment option granted by the Company in the foregoing August 2019 public offering resulting in net proceeds of $148,800 after deducting placement agent commissions. The transition from 2018 and 2019 led into 2020 such that the continuing operations of the Company are no longer dependent upon financing the cost of product development in the absence of revenues, but rather now upon our abilities to finance our efforts to successfully ramp up commercialization, thus earning the product validation of both customer licensing and purchases and creating a dynamic in which public and private offerings facilitate the growth of revenues, thus attracting investor support for continuing investment even as the revenues begin the reduction of the company’s dependence on capital raises over time. In January 2020, the Company closed two private placements of equity securities resulting in net proceeds of approximately $1,711,124 after deducting placement agent commissions and other offering expenses payable by the Company. As a result, the Company currently has sufficient cash and working capital to fund operations through the end of the first quarter of 2020 and is anticipating that contracts may be closed during fiscal 2020 generating additional cash flow in the near-term. In addition, the Company has access to public and private markets from which to derive additional financing to sustain operations beyond that term, if required; however the Company is unable to predict the extent to which the novel coronavirus may affect the financial markets and the Company’s access to such markets. There is no assurance that we will be successful in obtaining additional funding. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations. Loss Per Share – Year Ended December 31, 2019 2018 Warrants 363,727 305,060 Stock Options 180,903 82,627 Convertible Note Payable 2,500 2,500 Total Underlying Common Shares 547,130 390,187 Property and Equipment – In accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis. Income Taxes – The Company has no tax positions at December 31, 2019 and 2018 for which the ultimate deductibility is highly uncertain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the years ended December 31, 2019 and 2018, the Company recognized no interest and penalties. All tax years starting with 2016 are open for examination. Accounts Receivable and Allowance for Doubtful Accounts Long-Lived and Intangible Assets ® Cash Equivalents Concentration of Credit Risk - Stock Based Compensation Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 505, “Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification. Amortization Accounting Estimates Revenue Recognition – Revenue from Contracts with Customers In general, we determine revenue recognition by: (1) identifying the contract, or contracts, with our customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to performance obligations in the contract; and (5) recognizing revenue when, or as, we satisfy performance obligations by transferring the promised goods or services. Deferred Stock Offering Costs Inventory Research and Development

Notes Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Notes Receivable	NOTE 2 - Notes Receivable On May 1, 2017, the Company made a loan in the principal amount of $250,000 to Jaguar Precision Machine, LLC, a New Mexico limited liability company (“Jaguar”), pursuant to a Secured Convertible Promissory Note dated May 1, 2017 delivered by Jaguar to the Company. The loan bears interest at the rate of 7% per annum, was originally due and payable in full on August 1, 2018, is secured by certain assets of Jaguar, and is convertible at the Company’s option into 10% of the outstanding shares of the common stock of Jaguar unless Jaguar exercises its right under specified circumstances to repay all principal and accrued interest on the loan. On June 15, 2018, the Company received a $150,000 payment from Jaguar, $17,803 of which was applied to accumulated interest through that date and $132,197 was applied to the principal balance of the note. The December 31, 2018 principal balance of the note was $117,803 and the accumulated interest balance due was $4,110. During the year ended 2019 payments totaling $45,000 were received. The payments were applied first to the accumulated interest balance on the note and then to the remaining principal balance. On September 5, 2019, Jaguar paid the promissory note in full, including accrued interest.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory	NOTE 3 - Inventory At December 31, 2019 and December 31, 2018, the Company’s inventory was comprised of: December 31 2019 December 31, 2018 Raw Materials $ 173,102 $ 168,623 Work in Process 92,493 46,688 Finished Goods 333,123 24,775 Total Inventory $ 598,718 $ 240,086

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 4 – Property and Equipment The following is a summary of property and equipment, less accumulated depreciation, as of December 31, 2019 and 2018: Year Ended December 31, 2019 2018 Property and Equipment $ 1,108,375 $ 1,074,888 Less: Accumulated Depreciation (979,652 ) (796,944 ) Net Property and Equipment $ 128,723 $ 277,944 Depreciation expense on property and equipment was $182,708 and $190,280 for the years ended December 31, 2019 and 2018, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 5 – Intangible Assets The Company’s intangible assets consist of Patents and Patent Pending Applications. Provisional patent applications are not amortized until a patent has been granted. Once a patent is granted, the Company will amortize the related costs over the estimated useful life of the patent. If a patent application is denied, then the costs will be expensed at that time. During 2019, the Company wrote off $23,909 of patent costs related to PrintRite3D ® The following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2019 and 2018, respectively: Year Ended December 31, 2019 2018 Provisional Patent Applications $ 448,714 $ 366,353 Patents 138,936 47,073 Less: Accumulated Amortization (18,309 ) (8,448 ) Net Intangible Assets $ 569,341 $ 404,978 Amortization expense on intangible assets was $9,861 and $2,094 for the years ended December 31, 2019 and 2018, respectively. The estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows: 2020 $ 8,173 2021 8,173 2022 8,173 2023 8,173 Thereafter 87,936 $ 120,628

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	NOTE 6 - Notes Payable In April 2018, the Company entered into an amendment of the remaining $100,000 Secured Convertible Promissory Notes and Warrants which extended the payment due date to October 18, 2018, deleted the covenant providing for acceleration of the payment due date in the event of a public offering closing of at least $3,000,000 and required the Company to pay the balance of accrued and unpaid interest as of the effective date of the amendment. The Company paid the $8,761 balance of accrued interest to the holder in April 2018. In May 2018 the Holder Converted $50,000 of the Note principal into 2,500 shares of common stock and executed a cashless exercise of 2,400 of the warrants for an additional 480 shares of common stock. In October 2018, the Note was amended pursuant to which the due date was extended to April 18, 2019. Under the amendment, Sigma paid the $3,444 total accrued interest balance as of October 18, 2018 and agreed to make future payment dates of accrued interest on December 31, 2018 and April 18, 2019. In April 2019, the Note was amended pursuant to which the due date was extended to October 18, 2019. Under the amendment, Sigma paid the $2,514 total accrued interest balance through April 18, 2019 and agreed to make future payment dates of accrued interest on October 19, 2019. In October 2019, the Note was amended pursuant to which the due date was extended to January 3, 2020. Under the amendment, Sigma paid the $2,556 total accrued interest balance through October 18, 2019 and agreed to make future payment dates of accrued interest on January 3, 2020. At December 31, 2019 the Company had the remaining $50,000 Convertible Note outstanding plus accrued interest of $1,028.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity	NOTE 7 – Stockholders’ Equity Common Stock Effective February 27, 2020, our Articles of Incorporation were amended to provide for a reverse stock split of the outstanding shares of our common stock on a 1-for-10 basis (the “Reverse Stock Split”), and a corresponding decrease in the number of shares of our common stock that we are authorized to issue (the “Share Decrease”). The effects of the stock split have been retroactively reflected to all periods presented. In January 2019, the Company issued 20,000 shares of common stock to directors valued at $15.00 per share, or $300,000, with such shares to vest ratably over four quarterly installments, subject in each case to such director’s continuing service as a director. Also in January 2019, the Company issued 8,843 shares of common stock upon the cashless exercise of Unit Purchase Options issued in our June 2018 public offering. In January and February 2019, the Company issued a total of 7,023 shares of common stock upon the exercise of 7,023 warrants having an exercise price of $10.80 resulting in gross cash proceeds of $75,848. In March 2019, the Company issued 150 shares of common stock valued at $20.00 per share to the Company’s Vice President of Business Development in connection with his achievement of performance milestones, with such shares vesting immediately. Also in March 2019, the Company closed a public offering of equity securities in which it issued 140,080 shares of common stock and warrants to purchase a total of 42,024 shares of common stock resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by the Company. In May 2019, the Company closed a private placement of equity securities in which it issued 40,000 shares of common stock and warrants to purchase a total of 22,000 shares of common stock resulting in net proceeds of approximately $515,000, after deducting placement agent commissions and other offering expenses payable by the Company. On August 2, 2019, the Company closed a public offering of equity securities in which it issued 287,500 shares of common stock resulting in net proceeds of approximately $1,971,000, after deducting commissions and other offering expenses payable by the Company. On August 15, 2019, the Company issued 2,500 shares of common stock valued at $6.84 per share to MHZCI, LLC, an investor relations firm engaged by the Company, as partial compensation for services to be rendered. On September 13, 2019, Aegis Capital Corp. partially exercised its over-allotment option granted by the Company in the foregoing August 2019 public offering by purchasing an additional 20,000 shares of common stock, resulting in net proceeds of $148,800 after deducting commissions. During 2018, the Company issued 20,000 shares of common stock valued at $12.80 per share as compensation for serviced, totaling $256,264. In May 2018, we issued an aggregate of 100,000 shares of common stock upon conversion of the 1,000 shares of Series B Preferred Stock issued in April 2018 (as described below under “Preferred Stock”). In May 2018, the Company issued 2,980 shares of common stock as the result of a conversion of the $50,000 principal balance of Notes Payable and the cashless exercise of 2,400 warrants. In June 2018, as part of its public offering of equity securities described in Note 1, the Company issued 350 shares of Series C convertible preferred stock, 204,000 shares of common stock, and warrants to purchase a total of 71,700 shares of common stock (including the warrants described under “Preferred Stock” below that were issued on June 26, 2018). Each warrant has an initial price of $10.80 per share. The net proceeds to the Company were approximately $2,068,900 after commissions and other offering expenses. The Company also issued to Dawson James Securities, Inc., its placement agent in the public offering, a Unit Purchase Option to acquire up to 19,120 Units, at an exercise price of $12.50 per Unit, consisting of 19,120 shares of common stock and warrants to purchase up to 5,736 shares of common stock at an exercise price of $10.80 as compensation. Between August and October 2018, the Company issued 35,000 shares of common stock upon conversion of 350 shares of Series C Preferred Stock issued in June 2018 (as described below under “Preferred Stock”). Between October and December 2018, the Company issued 17,790 shares of common stock as the result of the exercise of warrants resulting in cash proceeds of $192,132. Deferred Compensation In previous years and 2019, the Company issued to various employees, directors, and contractors shares of the Company’s common stock, subject to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”). Such shares were valued at the fair value at the date of issue. The fair value was expensed as compensation over the vesting period and recorded as a reduction of stockholders’ equity. During 2019 and 2018, $303,000 and $277,515, respectively, of the unvested compensation cost related to these issues was recognized. As of December 31, 2019, and 2018, the balance of unvested compensation to be recognized was $0 and $21,355, respectively, and is recorded as prepaid stock compensation as of those dates. Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, $0.001 par value. No shares of preferred stock were issued and outstanding at December 31, 2019 or 2018. In April 2018, the Company issued 1,000 shares of the Company’s newly-created non-voting Series B Convertible Preferred Stock, which were convertible into 100,000 shares of common stock and warrants to purchase an aggregate of 75,000 shares of the Company’s common stock, for an aggregate purchase price of $1,000,000. The Series B Convertible Preferred Stock was fully converted into shares of common stock during 2018. The warrants have an initial exercise price of $14.70 per share, the closing price of the Company’s common stock reported on The NASDAQ Capital Market on April 6, 2018, subject to adjustment in certain circumstances. The net proceeds to the Company were approximately $877,500 after commissions and other offering expenses. The Company also issued to Dawson James Securities, Inc., its placement agent in the foregoing private placement, warrants to purchase up to 14,000 shares of common stock, at an exercise price of $14.70 per share, as compensation. The warrants issued pursuant to this transaction are unexercised as of December 31, 2019. In June 2018, as part of the public offering described in Note 1, the Company issued 350 shares of the Company’s newly-created non-voting Series C Convertible Preferred Stock, which were convertible into 35,000 shares of common stock, and warrants to purchase an aggregate of 10,500 shares of the Company’s common stock. The warrants have an initial exercise price of $10.80 per share, 11% above the closing price of the Company’s common stock reported on The NASDAQ Capital Market on June 26, 2018, subject to adjustment in certain circumstances. Stock Options In July 2019, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 75,000 shares of our common stock to a total of 240,000 shares. As of December 31, 2019, an aggregate of 8,211 shares of common stock were reserved for issuance under the 2013 Plan. During 2019, the Company granted a total of 100,326 options to 22 employees and 2 consultants with vesting periods ranging from immediately/upon issue to 4 years beginning January 1, 2019. In 2019, 38,143 options vested and $494,240 of compensation cost was recognized during the year. As of December 31, 2019, there were options to purchase 180,903 shares issued and outstanding under the 2013 Plan. Of this amount, there are vested options exercisable for 88,163 shares of common stock. No options were exercised during the year ended December 31, 2019. During 2018, the Company granted a total of 53,433 options to 18 employees and 1 consultant with vesting periods ranging from immediately/upon issue to 4 years beginning February 2018. In 2018, 41,549 options vested and $868,015 of compensation cost was recognized during the year. As of December 31, 2018, there were options to purchase 82,627 shares issued and outstanding under the 2013 Plan. Of this amount, there are vested options exercisable for 50,098 shares of common stock. No options were exercised during the year ended December 31, 2018. The Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s stock on the dates of grant. Stock options are typically granted throughout the year and generally vest over four years of service and expire ten years from the date of the award, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the requisite service period for each stock option award. Total share-based compensation expense included in the statements of operations for the years ended December 31, 2019 and 2018 is $797,238, of which $494,240 is related to stock options, and $1,145,530, of which $868,015 is related to stock options, respectively. There was no capitalized share-based compensation cost as of December 31, 2019 and 2018, and there were no recognized tax benefits during the years ended December 31, 2019 and 2018. To estimate the value of an award, the Company uses the Black-Scholes option-pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. The forfeiture rate also impacts the amount of aggregate compensation. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life, volatility and forfeiture rate are derived primarily from the Company’s historical data, the risk-free rate is based on the yield available on U.S. Treasury constant maturity rates with similar terms to the expected term of the stock option awards. The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2019 and 2018: Assumptions: 2019 2018 Dividend yield 0.00 0.00 Risk-free interest rate 1.42-2.53 % 2.68-3.10 % Expected volatility 105.2-112.1 % 104.9-137.3 % Expected life (in years) 5-10 5-10 Option activity for the year ended December 31, 2019 and 2018 was as follows: Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic Options ($) Life (Yrs.) Value ($) Options outstanding at December 31, 2017 29,994 4.57 7.33 16,600 Granted 53,433 1.45 6.58 0 Exercised - - - - Forfeited or cancelled (8,00 ) 4.59 - - Options outstanding at December 31, 2018 82,627 2.49 6.47 60,090 Granted 100,326 1.25 4.79 - Exercised - - - - Forfeited or cancelled (2,050 ) 1.68 - - Options outstanding at December 31, 2019 180,903 1.81 5.09 25,988 Options expected to vest in the future as of December 31, 2019 92,740 1.38 4.88 1,792 Options exercisable at December 31, 2019 88,163 2.27 5.30 24,196 Options vested, exercisable, and options expected to vest at December 31, 2019 180,903 1.81 5.09 25,988 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the $9.82 closing price of our Common Stock on December 31, 2019. Six of the 2019 option grants have an exercise price currently below $9.82. At December 31, 2019, there was $793,796 of unrecognized share-based compensation expense related to unvested share options with a weighted average remaining recognition period of 4.88 years. Warrants At December 31, 2019, the Company had outstanding warrants to purchase a total of 363,727 shares of common stock; 162,150 warrants at an exercise price of $40.00 per share, which if not exercised, will expire on February 21, 2022, 89,000 warrants at an exercise price of $14.70 per share, which if not exercised, will expire on October 07, 2023, 46,887 warrants at an exercise price of $10.80 per share, which if not exercised, will expire on June 26, 2023, 42,024 warrants at an exercise price of $16.10 per share, which if not exercised, will expire on March 15, 2024, 20,000 warrants with an exercise price of $15.60 per share, which if not exercised, will expire on May 7, 2024, 2,000 warrants with an exercise price of $17.50 per share, which if not exercised, will expire on May 7, 2024, and 1,666 warrants with an exercise price of $0.10, which if not exercised, will expire on November 18, 2022. Warrant activity for the year ended December 31, 2019 and 2018 was as follows: Weighted Average Weighted Average Exercise Remaining Price Contractual Warrants ($) Life (Yrs.) Warrants outstanding at December 31, 2017 164,550 39.70 4.11 Granted 160,700 13.00 4.64 Exercised (20,190 ) 11.90 - Forfeited or cancelled - - - Options outstanding at December 31, 2018 305,060 27.50 3.86 Granted 65,690 15.60 4.39 Exercised (7,023 ) 10.80 - Forfeited or cancelled - - - Warrants outstanding at December 31, 2019 363,727 25.60 3.12

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 – Income Taxes The Company accounts for income taxes in accordance with ASC Topic No. 740. This standard requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting methods and any available operating loss or tax credit carryforwards. Income tax returns open for examination by the Internal Revenue Service consist of tax years ended December 31, 2016 through 2018. The Company has available at December 31, 2019, unused operating loss carryforwards of approximately $14,469,000, which may be applied against future taxable income and which expire in various years through 2039. However, if certain substantial changes in the Company’s ownership should occur, there could be an annual limitation on the amount of net operating loss carryforward which can be utilized. The amount of and ultimate realization of the benefits from the operating loss carryforwards for income tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company and other future events, the effects of which cannot be determined. Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect of the loss carryforwards and other temporary differences of approximately $3,037,800 and $2,123,700 at December 31, 2019 and 2018, respectively, and, therefore, no deferred tax asset has been recognized for the loss carryforwards. Deferred tax assets are comprised of the following: 2019 2018 Deferred tax assets: NOL carryover $ 3,038,600 $ 2,105,600 Depreciation (800 ) 18,100 Valuation allowance (3,037,800 ) (2,123,700 ) Net deferred tax asset $ - $ - The reconciliation of the provision for income taxes computed at the U.S. federal statutory tax rate (21%) to the Company’s effective tax rate for the years ended December 31, 2019 and 2018 is as follows: 2019 2018 Book Loss $ (1,327,400 ) $ (1,170,600 ) Depreciation 19,000 13,400 Meals & Entertainment 167,420 2,600 Stock Compensation 1,900 242,730 Loss on Asset Disposal - 7,714 Change in valuation allowance 1,139,080 904,156 Provision for Income Taxes $ - $ -

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Loss Per Share	NOTE 9 – Loss Per Share The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended December 31, 2019 and 2018: Year Ended December 31 2019 2018 Loss from continuing Operations available to Common stockholders (numerator) $ (6,320,849 ) $ (5,574,163 ) Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) 1,176,278 689,805 Dilutive loss per share was not presented as the Company’s outstanding warrants, stock options and note conversion features common equivalent shares for the periods presented would have had an anti-dilutive effect. At December 31, 2019, the Company had outstanding 363,727 warrants which could be converted to 363,727 shares of common stock, a $50,000 note payable convertible into 2,500 shares of common stock, and 180,903 stock options exercisable for 180,903 shares of common stock resulting in a potential total additional 475,130 common stock shares outstanding in the future. At December 31, 2018, the Company had outstanding 305,050 warrants which could be converted to 305,060 shares of common stock, a $50,000 note payable convertible into 2,500 shares of common stock, and 82,627 stock options exercisable for 82,627 shares of common stock resulting in a potential total additional 390,187 common stock shares outstanding in the future.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 10 – Commitments and Contingencies Operating Leases

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations	NOTE 11 – Concentrations Revenues Customer 2019 2018 A 27.42 % - B 21.2 % 12.87 % C 20.34 % - D 11.83 % 23.34 % E - 12.62 % F - 12.18 % Accounts Receivable Customer 2019 2018 A 76.46 % - B 23.54 % - C - 64.43 % D - 17.01 % E - 12.11 %

Joint Venture

Joint Venture	12 Months Ended
	Dec. 31, 2019
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture	NOTE 12 - Joint Venture In July 2015, we entered into a joint venture agreement with Arete Innovative Solutions LLC (“Arete”). The Joint Venture was not consolidated, but rather was accounted for on the equity method of recording investments. There were no operating activities during the fiscal 2017 and net operations resulted in a loss on the investment of $105 in fiscal 2016. The Company and Arete agreed in 2017 to terminate the Joint Venture and are in the process of paying final costs. The remaining cash asset of the company will be distributed to the former partners in 2020.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2019
Defined Contribution Plan
Defined Contribution Plan	NOTE 13 - Defined Contribution Plan In 2014, the Company adopted a qualified 401(K) plan (“the Plan”), in which all employees over the age of 21 may participate. The Company has elected to match 100% of each participant’s contribution up to 3% of salary, and 50% of the next 2% of salary contributed. The costs of matching contributions were $45,080 in 2019 and $51,415 in 2018.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 14 – Related Party Transactions On June 17, 2019, our Former Chief Financial Officer, Nannette Toups submitted notice to the Company of her resignation effective August 15, 2019. On September 12, 2019, Ms. Toups Separation Agreement was amended to change her Effective Date to September 15, 2019. Effective September 15, 2019 the Company entered into a one-year Consulting Agreement with Ms. Toups as an independent contractor to provide non-exclusive consulting services to the Company on as an-needed basis at the rate of $100 per hour. The agreement provides that as long as the Consulting Agreement remains in effect, the stock options of the Company held by Ms. Toups shall remain exercisable and continue to vest in accordance with the terms of the Consultants existing stock options agreements of the Company. Through December 31, 2019, Ms. Toups has accrued $4,000 in fees for services rendered under the Consulting Agreement.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 15 – Subsequent Events In January 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the “Institutional Private Placement”). Pursuant to the SPA, the Company issued and sold 1,640 shares of the Company’s Series D Convertible Preferred Stock (the “Series D Preferred Stock”), warrants to purchase 779,600 shares of the Company’s Common Stock (the “Common Warrants”) and warrants to purchase 6,156 shares of the Series D Preferred Stock (the “Preferred Warrants”) for a total gross purchase price of $1,600,000. The Series D Preferred Stock is initially convertible into 164,000 shares of Common Stock, the Preferred Warrants have an initial exercise price of $975.00 per share, and the Common Warrants have an initial exercise price of $10.00 per share. Concurrent with the Institutional Private Placement, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain of its directors and the Company’s largest shareholder (the “Other Private Placement”). Pursuant to the SPA, the Company issued and sold 333.33 shares of the Company’s Series E Convertible Preferred Stock (the “Series E Preferred Stock”), and Class A Warrants to purchase 48,544 shares of the Company’s Common Stock (the “Common Warrants”) for a total gross purchase price of $500,000. The Series E Preferred Stock is initially convertible into 48,544 shares of Common Stock, and the Class A Warrants have an initial exercise price of $11.30 per share. Sigma also issued Dawson James Securities, Inc., its placement agent in the foregoing private placement, warrants to purchase up to 17,004 shares of Common Stock, at an initial exercise price of $11.30 per share as partial compensation. Total net proceeds from the private placements were approximately $1,711,124, after deducting placement commissions and other offering expenses payable by the Company. On January 31, 2020, the Company paid off its Secured Convertible Promissory Note in full in the amount of $56,458, including accrued interest of $1,458 and a late fee penalty of $5,000. Effective February 27, 2020, our Amended and Restated Articles of Incorporation were amended pursuant to a Certificate of Change Pursuant to Nevada Revised Statutes 78.209 (the “Certificate of Change”) filed with the Nevada Secretary of State. The Certificate of Change provided for both a reverse stock split of the outstanding shares of our common stock on a 1-for-10 basis (the “Reverse Stock Split”), and a corresponding decrease in the number of shares of our common stock that we are authorized to issue (the “Share Decrease”). As a result of the Reverse Stock Split, the number of issued and outstanding shares of our common stock decreased from 14,500,823 pre-Reverse Stock Split shares to 1,450,082 post-Reverse Stock Split shares (after adjustment for any fractional shares). Pursuant to the Share Decrease, the number of authorized shares of our common stock decreased from 22,500,000 to 2,500,000 shares of common stock, $0.001 par value per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Nature of Business	Nature of Business
Reverse Stock Split	Reverse Stock Split
Basis of Presentation	Basis of Presentation
Continuing Operations	Continuing Operations In 2019, the Company relied on both public and private offerings to finance the commencement of commercialization by entering test and evaluation programs with large potential customers, both end-users and OEMs. On March 15, 2019, the Company closed a public offering of equity securities resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by the Company. In May 2019, the Company closed a private placement of equity securities resulting in net proceeds of approximately $515,000, after deducting placement agent commissions and other offering expenses payable by the Company. In August 2019, the Company closed a public offering of equity securities resulting in net proceeds of approximately $1,971,000, after deducting placement agent commissions and other offering expenses payable by the Company. In September 2019, Aegis Capital Corp. partially exercised its over-allotment option granted by the Company in the foregoing August 2019 public offering resulting in net proceeds of $148,800 after deducting placement agent commissions. The transition from 2018 and 2019 led into 2020 such that the continuing operations of the Company are no longer dependent upon financing the cost of product development in the absence of revenues, but rather now upon our abilities to finance our efforts to successfully ramp up commercialization, thus earning the product validation of both customer licensing and purchases and creating a dynamic in which public and private offerings facilitate the growth of revenues, thus attracting investor support for continuing investment even as the revenues begin the reduction of the company’s dependence on capital raises over time. In January 2020, the Company closed two private placements of equity securities resulting in net proceeds of approximately $1,711,124 after deducting placement agent commissions and other offering expenses payable by the Company. As a result, the Company currently has sufficient cash and working capital to fund operations through the end of the first quarter of 2020 and is anticipating that contracts may be closed during fiscal 2020 generating additional cash flow in the near-term. In addition, the Company has access to public and private markets from which to derive additional financing to sustain operations beyond that term, if required; however the Company is unable to predict the extent to which the novel coronavirus may affect the financial markets and the Company’s access to such markets. There is no assurance that we will be successful in obtaining additional funding. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations.
Loss Per Share	Loss Per Share – Year Ended December 31, 2019 2018 Warrants 363,727 305,060 Stock Options 180,903 82,627 Convertible Note Payable 2,500 2,500 Total Underlying Common Shares 547,130 390,187
Property and Equipment	Property and Equipment – In accordance with its policy, the Company reviews the estimated useful lives of its fixed assets on an ongoing basis.
Income Taxes	Income Taxes – The Company has no tax positions at December 31, 2019 and 2018 for which the ultimate deductibility is highly uncertain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the years ended December 31, 2019 and 2018, the Company recognized no interest and penalties. All tax years starting with 2016 are open for examination.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
Long-Lived and Intangible Assets	Long-Lived and Intangible Assets ®
Cash Equivalents	Cash Equivalents
Concentration of Credit Risk	Concentration of Credit Risk -
Stock Based Compensation	Stock Based Compensation Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC Topic No. 505, “Equity Based Payments to Non-Employees.” In general, the measurement date is either (a) when a performance commitment, as defined, is reached or (b) the earlier of the date that (i) the non-employee performance requirement is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in the FASB Accounting Standards Codification.
Amortization	Amortization
Accounting Estimates	Accounting Estimates
Revenue Recognition	Revenue Recognition – Revenue from Contracts with Customers In general, we determine revenue recognition by: (1) identifying the contract, or contracts, with our customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to performance obligations in the contract; and (5) recognizing revenue when, or as, we satisfy performance obligations by transferring the promised goods or services.
Deferred Stock Offering Costs	Deferred Stock Offering Costs
Inventory	Inventory
Research and Development	Research and Development

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At December 31, 2019 and 2018, the Company had the following common shares underlying these instruments: Year Ended December 31, 2019 2018 Warrants 363,727 305,060 Stock Options 180,903 82,627 Convertible Note Payable 2,500 2,500 Total Underlying Common Shares 547,130 390,187

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	At December 31, 2019 and December 31, 2018, the Company’s inventory was comprised of: December 31 2019 December 31, 2018 Raw Materials $ 173,102 $ 168,623 Work in Process 92,493 46,688 Finished Goods 333,123 24,775 Total Inventory $ 598,718 $ 240,086

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The following is a summary of property and equipment, less accumulated depreciation, as of December 31, 2019 and 2018: Year Ended December 31, 2019 2018 Property and Equipment $ 1,108,375 $ 1,074,888 Less: Accumulated Depreciation (979,652 ) (796,944 ) Net Property and Equipment $ 128,723 $ 277,944

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Definite-life Intangible Assets and Accumulated Amortization	The following is a summary of definite-life intangible assets less accumulated amortization as of December 31, 2019 and 2018, respectively: Year Ended December 31, 2019 2018 Provisional Patent Applications $ 448,714 $ 366,353 Patents 138,936 47,073 Less: Accumulated Amortization (18,309 ) (8,448 ) Net Intangible Assets $ 569,341 $ 404,978
Schedule of Aggregate Amortization Expense	The estimated aggregate amortization expense for each of the succeeding years ending December 31 is as follows: 2020 $ 8,173 2021 8,173 2022 8,173 2023 8,173 Thereafter 87,936 $ 120,628

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the years ended December 31, 2019 and 2018: Assumptions: 2019 2018 Dividend yield 0.00 0.00 Risk-free interest rate 1.42-2.53 % 2.68-3.10 % Expected volatility 105.2-112.1 % 104.9-137.3 % Expected life (in years) 5-10 5-10
Schedule of Stock Option Activity	Option activity for the year ended December 31, 2019 and 2018 was as follows: Weighted Average Weighted Average Exercise Remaining Aggregate Price Contractual Intrinsic Options ($) Life (Yrs.) Value ($) Options outstanding at December 31, 2017 29,994 4.57 7.33 16,600 Granted 53,433 1.45 6.58 0 Exercised - - - - Forfeited or cancelled (8,00 ) 4.59 - - Options outstanding at December 31, 2018 82,627 2.49 6.47 60,090 Granted 100,326 1.25 4.79 - Exercised - - - - Forfeited or cancelled (2,050 ) 1.68 - - Options outstanding at December 31, 2019 180,903 1.81 5.09 25,988 Options expected to vest in the future as of December 31, 2019 92,740 1.38 4.88 1,792 Options exercisable at December 31, 2019 88,163 2.27 5.30 24,196 Options vested, exercisable, and options expected to vest at December 31, 2019 180,903 1.81 5.09 25,988
Summary of Warrant Activity	Warrant activity for the year ended December 31, 2019 and 2018 was as follows: Weighted Average Weighted Average Exercise Remaining Price Contractual Warrants ($) Life (Yrs.) Warrants outstanding at December 31, 2017 164,550 39.70 4.11 Granted 160,700 13.00 4.64 Exercised (20,190 ) 11.90 - Forfeited or cancelled - - - Options outstanding at December 31, 2018 305,060 27.50 3.86 Granted 65,690 15.60 4.39 Exercised (7,023 ) 10.80 - Forfeited or cancelled - - - Warrants outstanding at December 31, 2019 363,727 25.60 3.12

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets are comprised of the following: 2019 2018 Deferred tax assets: NOL carryover $ 3,038,600 $ 2,105,600 Depreciation (800 ) 18,100 Valuation allowance (3,037,800 ) (2,123,700 ) Net deferred tax asset $ - $ -
Schedule of Reconciliation of the Provision for Income Taxes	2019 2018 Book Loss $ (1,327,400 ) $ (1,170,600 ) Depreciation 19,000 13,400 Meals & Entertainment 167,420 2,600 Stock Compensation 1,900 242,730 Loss on Asset Disposal - 7,714 Change in valuation allowance 1,139,080 904,156 Provision for Income Taxes $ - $ -

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following data show the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended December 31, 2019 and 2018: Year Ended December 31 2019 2018 Loss from continuing Operations available to Common stockholders (numerator) $ (6,320,849 ) $ (5,574,163 ) Weighted average number of common shares Outstanding used in loss per share during the Period (denominator) 1,176,278 689,805

Concentrations (Tables)

Concentrations (Tables)	12 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Schedule of Concentration of Risks	The change in the composition of customers between the two years resulted primarily from the change of focus from sales to R&D customers to Proof of Concept sales to customers preparing to initiate commercial production. Customer 2019 2018 A 27.42 % - B 21.2 % 12.87 % C 20.34 % - D 11.83 % 23.34 % E - 12.62 % F - 12.18 % Accounts Receivable Customer 2019 2018 A 76.46 % - B 23.54 % - C - 64.43 % D - 17.01 % E - 12.11 %

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Feb. 27, 2020	Jan. 30, 2020	Sep. 30, 2019	Aug. 31, 2019	May 31, 2019	Mar. 31, 2019	Jun. 30, 2018	Apr. 30, 2018	Jan. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Proceeds form public offering of equity securities			$ 148,800	$ 1,971,000	$ 515,000	$ 1,679,230	$ 2,068,900	$ 877,500
Income tax interest and penalties
Allowance for doubtful accounts receivable
Finite-lived intangible asset, useful life										17 years
Research and development costs										$ 647,994	$ 493,410
Dental Patents [Member]
Write off intangible asset									$ 50,255
PrintRite3D [Member]
Write off intangible asset										23,909
March 15, 2019 [Member]
Proceeds form public offering of equity securities										$ 1,679,230
Subsequent Event [Member]
Reverse stock split, description	1-for-10 basis
Proceeds form public offering of equity securities		$ 1,711,124

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities excluded from computation of earnings per share, amount	547,130	390,187
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	363,727	305,060
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount	180,903	82,627
Convertible Note Payable [Member]
Antidilutive securities excluded from computation of earnings per share, amount	2,500	2,500

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)	Jun. 15, 2018	May 01, 2017	Dec. 31, 2019	Dec. 31, 2018
Secured Convertible Promissory Note [Member]
Interest rate		10.00%
Promissory Note [Member]
Debt principal amount				$ 117,803
Proceeds from notes receivable			$ 45,000
Debt accumulated interest				$ 4,110
Jaguar Precision Machine, LLC [Member] | Secured Convertible Promissory Note [Member]
Debt principal amount		$ 250,000
Interest rate		7.00%
Debt maturity period		Aug. 1, 2018
Jaguar Precision Machine, LLC [Member] | Promissory Note [Member]
Debt principal amount	$ 132,197
Proceeds from notes receivable	150,000
Debt accumulated interest	$ 17,803

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials	$ 173,102	$ 168,623
Work in Process	92,493	46,688
Finished Goods	333,123	24,775
Total Inventory	$ 598,718	$ 240,086

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 182,708	$ 190,280

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	$ 1,108,375	$ 1,074,888
Less: Accumulated Depreciation	(979,652)	(796,944)
Net Property and Equipment	$ 128,723	$ 277,944

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Amortization expense on intangible assets	$ 9,861	$ 2,094
PrintRite3D [Member]
Wrote off of patent cost	23,909
Patent [Member]
Wrote off of patent cost	$ 91,863

Intangible Assets - Summary of

Intangible Assets - Summary of Definite-life Intangible Assets and Accumulated Amortization (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Less: Accumulated Amortization	$ (18,309)	$ (8,448)
Net Intangible Assets	569,341	404,978
Provisional Patent Applications [Member]
Intangible Assets	448,714	366,353
Patents [Member]
Intangible Assets	$ 138,936	$ 47,073

Intangible Assets - Schedule of

Intangible Assets - Schedule of Aggregate Amortization Expense (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Intangible asset and amortization expense	$ 569,341	$ 404,978
Intangible Assets [Member]
2020	8,173
2021	8,173
2022	8,173
2023	8,173
Thereafter	87,936
Intangible asset and amortization expense	$ 120,628

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Dec. 31, 2018	May 31, 2018	Mar. 31, 2019	Feb. 28, 2019	Jan. 31, 2019	Jun. 30, 2018	May 31, 2018	May 31, 2018	Apr. 30, 2018	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Oct. 31, 2019	Apr. 30, 2019	Oct. 31, 2018
Payment for public offering of equity securities											$ 649,329	$ 433,700
Accrued interest													$ 2,556	$ 2,514	$ 3,444
Common stock issued during period	20,000		140,080	7,023	7,023	204,000		2,980		17,790
Holders [Member]
Accrued interest											1,028
Value of shares converted							$ 50,000
Common stock issued during period		480					2,500
Number of cashless exercise warrant shares		2,400					2,400	2,400
Convertible debt											$ 50,000
Secured Convertible Promissory Notes and Warrants [Member]
Remaining payment of debt									$ 100,000
Debt maturity date									Oct. 18, 2018
Payment for public offering of equity securities									$ 3,000,000
Accrued interest									$ 8,761

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Feb. 27, 2020	Sep. 13, 2019	Aug. 15, 2019	Aug. 02, 2019	Dec. 31, 2018	Jan. 30, 2020	Sep. 30, 2019	Aug. 31, 2019	Jul. 31, 2019	May 31, 2019	Mar. 31, 2019	Feb. 28, 2019	Jan. 31, 2019	Jun. 30, 2018	May 31, 2018	May 31, 2018	Apr. 30, 2018	Dec. 31, 2018	Oct. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jan. 31, 2020	Aug. 31, 2018
Common stock issued during period					20,000						140,080	7,023	7,023	204,000		2,980		17,790
Share price per share					$ 12.80								$ 10.80					$ 12.80			$ 12.80
Common stock issued during period, value												$ 75,848	$ 75,848
Warrants to purchase shares of common stock											42,024			71,700
Proceeds from public offering							$ 148,800	$ 1,971,000		$ 515,000	$ 1,679,230			$ 2,068,900			$ 877,500
Proceeds from issuance of common Stock and warrants																				$ 4,981,221	$ 2,040,100
Conversion of stock, shares converted															1,000
Notes payable principal balance															$ 50,000	$ 50,000
Warrant exercised															2,400	2,400
Warrants exercise price														$ 10.80
Unvested compensation cost					$ 277,515													$ 277,515		303,000	277,515
Unvested prepaid stock compensation					$ 21,355													$ 21,355		$ 0	$ 21,355
Preferred stock, shares authorized					10,000,000													10,000,000		10,000,000	10,000,000
Preferred stock, par value					$ 0.001													$ 0.001		$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Number of shares granted																				100,326	53,433
Number of option vested, exercisable																				180,903
Number of options exercised
Share based compensation																				$ 797,240	$ 1,145,530
Unrecognized share based compensation																				$ 793,796
Option term																				5 years 1 month 2 days	6 years 5 months 20 days
Options exercise price																				$ 9.82
Stock Options [Member]
Share based compensation																				$ 494,240	$ 868,015
2013 Stock Option Plan [Member]
Common stock issued during period									240,000
Common stock shares reserved for issaunce									75,000											8,211
Common Warrants [Member]
Proceeds from issuance of common Stock and warrants																		$ 192,132
Warrant [Member]
Warrants to purchase shares of common stock														10,500			75,000
Warrant exercised					305,050													305,050		363,727	305,050
Warrants exercise price														$ 10.80			$ 14.70
Common Stock [Member]
Aggregation of purchase price																	$ 1,000,000
Warrant One [Member]
Warrants to purchase shares of common stock																				363,727
Warrant Two [Member]
Warrants to purchase shares of common stock																				162,150
Warrants exercise price																				$ 40
Warrants expiration																				Feb. 21, 2022
Warrant Three [Member]
Warrants to purchase shares of common stock																				89,000
Warrants exercise price																				$ 14.70
Warrants expiration																				Oct. 7, 2023
Warrant Four [Member]
Warrants to purchase shares of common stock																				46,887
Warrants exercise price																				$ 10.80
Warrants expiration																				Jun. 26, 2023
Warrant Five [Member]
Warrants to purchase shares of common stock																				42,024
Warrants exercise price																				$ 16.10
Warrants expiration																				Mar. 15, 2024
Warrant Six [Member]
Warrants to purchase shares of common stock																				20,000
Warrants exercise price																				$ 15.60
Warrants expiration																				Nov. 8, 2024
Warrant Seven [Member]
Warrants to purchase shares of common stock																				2,000
Warrants exercise price																				$ 17.50
Warrants expiration																				Nov. 8, 2024
Warrant Eight [Member]
Warrants to purchase shares of common stock																				1,666
Warrants exercise price																				$ 0.10
Warrants expiration																				Nov. 18, 2022
Series B Convertible Preferred Stock [Member]
Common stock issued during period															1,000,000
Conversion of stock, shares converted														350
Series C Convertible Preferred Stock and Warrants [Member]
Conversion of stock, shares converted																			35,000
Conversion of preferred stock																			350				350
Series B Convertible Preferred [Member]
Common stock issued during period																	1,000
Conversion of stock, shares converted																	100,000
Series C Convertible Preferred [Member]
Common stock issued during period														350
Conversion of stock, shares converted														35,000
MHZCI, LLC [Member]
Common stock issued during period			2,500
Share price per share			$ 6.84
Dawson James Securities, Inc [Member]
Common stock issued during period														19,120
Share price per share														$ 12.50
Warrants to purchase shares of common stock														5,736
Warrants exercise price														$ 10.80
Option to acquire shares														19,120
Private Placement [Member]
Common stock issued during period										40,000
Warrants to purchase shares of common stock										22,000							14,000
Proceeds from public offering										$ 515,000
Warrants exercise price																	$ 14.70
Public Offering [Member]
Common stock issued during period				287,500
Proceeds from issuance of common Stock and warrants				$ 1,971,000
June 2018 Public Offering [Member]
Common stock issued during period													8,843
August 2019 Public Offering [Member]
Common stock issued during period		20,000
Proceeds from issuance of common Stock and warrants		$ 148,800
Directors [Member]
Common stock issued during period																				20,000
Share price per share																				$ 15
Common stock issued during period, value																				$ 300,000
Vice President Member]
Common stock issued during period											150
Share price per share											$ 20
22 Employees and 2 Consultants [Member]
Number of shares granted																				100,326
Vesting period																				4 years
Number of shares vested																				38,143
Stock options compensation cost																				$ 494,240
18 Employees and 1 Consultant [Member]
Number of shares granted																					53,433
Vesting period																					4 years
Number of shares vested																					41,549
Stock options compensation cost																					$ 868,015
18 Employees and 1 Consultant [Member] | 2013 Stock Option Plan [Member]
Number of shares granted																				180,903	86,627
Number of shares vested																				88,163	50,098
Subsequent Event [Member]
Reverse stock split	1-for-10 basis
Proceeds from public offering						$ 1,711,124
Subsequent Event [Member] | Dawson James Securities, Inc [Member]
Warrants to purchase shares of common stock																						17,004
Warrants exercise price																						$ 11.30

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Dividend yield	0.00%	0.00%
Risk-free interest rate, minimum	1.42%	2.68%
Risk-free interest rate, maximum	2.53%	3.10%
Expected volatility, minimum	105.20%	104.90%
Expected volatility, maximum	112.10%	137.30%
Minimum [Member]
Expected life (in years)	5 years	5 years
Maximum [Member]
Expected life (in years)	10 years	10 years

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Number of Options, Outstanding, Beginning Balance	82,627	29,994
Number of Options, Granted	100,326	53,433
Number of Options, Exercised
Number of Options, Forfeited or cancelled	(2,050)	(800)
Number of Options, Outstanding Ending Balance	180,903	82,627
Number of Options, Expected to Vest in the Future Ending Balance	92,740
Number of Options, Exercisable	88,163
Number of Options, Vested, Exercisable and Options Expected to Vest Ending Balance	180,903
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 2.49	$ 4.57
Weighted Average Exercise Price, Granted	1.25	1.45
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited or cancelled	1.68	4.59
Weighted Average Exercise Price, Outstanding	1.81	$ 2.49
Weighted Average Exercise Price, Expected to Vest	1.38
Weighted Average Exercise Price, Exercisable	2.27
Weighted Average Exercise Price, Vested, Exercisable and Options Expected to Vest	$ 1.81
Weighted Average Remaining Contractual Life, Outstanding Beginning	6 years 5 months 20 days	7 years 3 months 29 days
Weighted Average Remaining Contractual Life, Granted	4 years 9 months 14 days	6 years 6 months 29 days
Weighted Average Remaining Contractual Life, Outstanding	5 years 1 month 2 days	6 years 5 months 20 days
Weighted Average Remaining Contractual Life, Expected to Vest	4 years 10 months 17 days
Weighted Average Remaining Contractual Life, Exercisable	5 years 3 months 19 days
Weighted Average Remaining Contractual Life, Vested, Exercisable and Options Expected to Vest	5 years 1 month 2 days
Aggregate Intrinsic Value, Outstanding	$ 60,090	$ 16,600
Aggregate Intrinsic Value, Outstanding	25,988	$ 60,090
Aggregate Intrinsic Value, Options expected to vest in the future	1,792
Aggregate Intrinsic Value, Options exercisable	24,196
Aggregate Intrinsic Value, Options vested, exercisable and options expected to vest	$ 25,988

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Equity [Abstract]
Number of Shares, Warrants Outstanding, Beginning balance	305,060	164,550
Number of Shares, Warrants Granted	65,690	160,700
Number of Shares, Warrants Exercised	(7,023)	(20,190)
Number of Shares, Warrants Forfeited or Cancelled
Number of Shares, Warrants Outstanding, Ending balance	363,727	305,060
Weighted Average Exercise Price, Warrants outstanding, Beginning balance	$ 27.50	$ 39.70
Weighted Average Exercise Price, Warrants Granted	15.60	13
Weighted Average Exercise Price, Warrants Exercised	10.80	11.90
Weighted Average Exercise Price, Warrants Forfeited or cancelled
Weighted Average Exercise Price, Warrants outstanding, Ending balance	$ 25.60	$ 27.50
Weighted Average Remaining Contractual Life (Years), Warrants outstanding, Beginning balance	3 years 10 months 10 days	4 years 1 month 9 days
Weighted Average Remaining Contractual Life (Years), Warrants Grants	4 years 4 months 20 days	4 years 7 months 21 days
Weighted Average Remaining Contractual Life (Years), Warrants outstanding, Ending balance	3 years 1 month 13 days	3 years 10 months 10 days

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 14,469,000
Tax expiration description	expire in various years through 2039
Valuation allowance	$ 3,037,800	$ 2,123,700
Federal statutory tax rate	21.00%	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
NOL carryover	$ 3,038,600	$ 2,105,600
Depreciation	(800)	18,100
Valuation allowance	(3,037,800)	(2,123,700)
Net deferred tax asset

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of the Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Book Loss	$ (1,327,400)	$ (1,170,600)
Depreciation	19,000	13,400
Meals & Entertainment	167,420	2,600
Stock Compensation	1,900	242,730
Loss on Asset Disposal		7,714
Change in valuation allowance	1,139,080	904,156
Provision for Income Taxes

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	May 31, 2018
Warrants Outstanding			2,400
Stock options exercisable	88,163
Antidilutive securities excluded from computation of earnings per share, amount	547,130	390,187
Common stock, shares outstanding	1,403,759	877,663
Stock Option [Member]
Stock options exercisable	180,903	82,627
Antidilutive securities excluded from computation of earnings per share, amount	180,903	82,627
Common stock, shares outstanding	475,130	390,187
Convertible Debt [Member]
Convertible note payable	$ 50,000	$ 50,000
Convertible common stock shares	2,500	2,500
Warrant [Member]
Warrants Outstanding	363,727	305,050
Conversion of common stock	363,727	305,060

Loss Per Share - Schedule of Ea

Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Loss from continuing operations available to common stockholders (numerator)	$ (6,320,849)	$ (5,574,163)
Weighted average number of common shares outstanding used in loss per share during the period (denominator)	1,176,278	689,805

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Expense form operating leases	$ 73,255	$ 70,187
Non-cancellable operating leases	$ 28,305
Minimum lease payments description	The future minimum lease payments are due during the year 2020.

Concentrations (Details Narrati

Concentrations (Details Narrative)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues [Member]
Concentration of risk percentage	10.00%	10.00%
Accounts Receivable [Member]
Concentration of risk percentage	10.00%	10.00%

Concentrations - Schedule of Co

Concentrations - Schedule of Concentration of Risks (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues [Member]
Concentration of risk percentage	10.00%	10.00%
Revenues [Member] | Customer A [Member]
Concentration of risk percentage	27.42%	0.00%
Revenues [Member] | Customer B [Member]
Concentration of risk percentage	21.20%	12.87%
Revenues [Member] | Customer C [Member]
Concentration of risk percentage	20.34%	0.00%
Revenues [Member] | Customer D [Member]
Concentration of risk percentage	11.83%	23.34%
Revenues [Member] | Customer E [Member]
Concentration of risk percentage	0.00%	12.62%
Revenues [Member] | Customer F [Member]
Concentration of risk percentage	0.00%	12.18%
Accounts Receivable [Member]
Concentration of risk percentage	10.00%	10.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration of risk percentage	76.46%	0.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration of risk percentage	23.54%	0.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration of risk percentage	0.00%	64.43%
Accounts Receivable [Member] | Customer D [Member]
Concentration of risk percentage	0.00%	17.01%
Accounts Receivable [Member] | Customer E [Member]
Concentration of risk percentage	0.00%	12.11%

Joint Venture (Details Narrativ

Joint Venture (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity Method Investments and Joint Ventures [Abstract]
Operating activities	$ (5,514,805)	$ (3,762,971)
Loss on investment				$ 105

Defined Contribution Plan (Deta

Defined Contribution Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan
Contribution plan description	The Company has elected to match 100% of each participant's contribution up to 3% of salary, and 50% of the next 2% of salary contributed.
Cost of contribution	$ 45,080	$ 51,415

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Consulting Agreement [Member] - Ms. Toups [Member] - USD ($)	Sep. 15, 2019	Dec. 31, 2019
Agreement term	1 year
Non-exclusive consulting services	$ 100
Fees for services		$ 4,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 27, 2020	Jan. 31, 2020	Oct. 31, 2019	Apr. 30, 2019	Mar. 31, 2019	Oct. 31, 2018	Jun. 30, 2018
Warrants to purchase shares of common stock					42,024		71,700
Warrants exercise price							$ 10.80
Accrured interest			$ 2,556	$ 2,514		$ 3,444
Dawson James Securities, Inc [Member]
Warrants to purchase shares of common stock							5,736
Warrants exercise price							$ 10.80
Subsequent Event [Member]
Reverse stock split	1-for-10 basis
Reverse stock split, description	As a result of the Reverse Stock Split, the number of issued and outstanding shares of our common stock decreased from 14,500,823 pre-Reverse Stock Split shares to 1,450,082 post-Reverse Stock Split shares (after adjustment for any fractional shares). Pursuant to the Share Decrease, the number of authorized shares of our common stock decreased from 22,500,000 to 2,500,000 shares of common stock, $0.001 par value per share.
Subsequent Event [Member] | Secured Convertible Promissory Note [Member]
Repayments of convertible debt		$ 56,458
Accrured interest		1,458
Late fee penalty		$ 5,000
Subsequent Event [Member] | Dawson James Securities, Inc [Member]
Warrants to purchase shares of common stock		17,004
Warrants exercise price		$ 11.30
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Gross purchase price		$ 1,600,000
Subsequent Event [Member] | Series D Preferred Stock [Member] | Securities Purchase Agreement [Member]
Share issued and sold during period, shares		1,640
Conversion of preferred stock		164,000
Subsequent Event [Member] | Series D Preferred Stock [Member] | Securities Purchase Agreement [Member] | Common Warrants [Member]
Warrants to purchase shares of common stock		779,600
Warrants exercise price		$ 10
Subsequent Event [Member] | Series D Preferred Stock [Member] | Securities Purchase Agreement [Member] | Preferred Warrants [Member]
Warrants to purchase shares of common stock		6,156
Warrants exercise price		$ 975
Subsequent Event [Member] | Series E Preferred Stock [Member] | Other Private Placement [Member]
Share issued and sold during period, shares		333.33
Gross purchase price		$ 500,000
Gross proceeds from private placement		$ 1,711,124
Subsequent Event [Member] | Series E Preferred Stock [Member] | Class A Warrants [Member]
Warrants to purchase shares of common stock		48,544
Conversion of preferred stock		48,544
Warrants exercise price		$ 11.30